07/28/2026
COMPOUNDS ...
RETATRUTIDE, “GREY MARKET” PEPTIDES, AND COMPOUNDING: WHAT YOU NEED TO KNOW: July 26, 2027
We are increasingly seeing inquiries about retatrutide, fueled by media attention and early clinical trial results suggesting significant weight loss potential. While the interest is understandable, there is a critical need to separate scientific promise from what is currently legal, safe, and permissible in clinical practice.
Retatrutide is an investigational GIP, GLP-1, and glucagon receptor agonist that remains in Phase 3 clinical trials and has not received FDA approval for any indication. As such, it is not recognized as safe and effective under federal law.
From a compounding standpoint, the regulatory framework is clear:
Under Section 503A of the Federal Food, Drug, and Cosmetic Act, state-licensed compounding pharmacies may only compound using bulk drug substances that meet specific criteria. These include substances with a USP/NF monograph, those that are components of FDA-approved drugs, or those appearing on the FDA’s 503A bulks list. Retatrutide meets none of these criteria.
Similarly, under Section 503B, outsourcing facilities are limited to compounding substances that appear on the FDA’s 503B bulks list or are on the drug shortage list. Retatrutide is on neither list.
Because of this, compounded retatrutide does not qualify for exemptions under federal law. The FDA has explicitly stated that products containing retatrutide are considered unapproved new drugs and are not eligible for compounding pathways. Any pharmacy producing or distributing it is operating outside of established regulatory frameworks.
State laws further reinforce this structure. While state boards of pharmacy oversee traditional compounding practice, they do so within the boundaries of federal law. State authority does not create an independent pathway to compound substances that fail to meet federal requirements.
This has led to the emergence of a “grey market” for peptides, including retatrutide. These products are often sold online as “research use only” or “not for human consumption,” allowing vendors to attempt to bypass regulatory oversight. In reality, these products exist entirely outside the regulated drug supply chain. They are not subject to FDA review, are not manufactured under Good Manufacturing Practices, and have no assurances of purity, potency, sterility, or accurate dosing.
Reports have highlighted additional concerns in this space, including contamination, mislabeled concentrations, counterfeit products, and direct-to-consumer sales without medical oversight. These risks are not theoretical—they reflect the predictable consequences of bypassing established regulatory safeguards.
It is also important to distinguish compounding from manufacturing. Compounding is intended to meet specific patient needs when an FDA-approved option is not available or appropriate. It is not a mechanism to introduce new, unapproved drugs into clinical use or to replicate investigational therapies.
At present, there is no lawful pathway for a licensed compounding pharmacy to prepare, dispense, or facilitate access to retatrutide. Any claims to the contrary warrant careful scrutiny, including asking for the specific regulatory basis being used—there is currently no compliant answer.
Consequently, this office and its staff cannot recommend, prescribe, or support the use of compounded retatrutide or any products obtained through grey market channels.
We will continue to monitor FDA guidance and the progress of clinical trials. If and when retatrutide receives FDA approval or becomes eligible for compounding under established law, the landscape may change.
Until then, the position remains unchanged: retatrutide cannot be legally compounded, and products marketed as such fall outside the safeguards designed to protect patients.
Send a message to learn more
